ticlopidine has been researched along with Heart Diseases in 60 studies
Ticlopidine: An effective inhibitor of platelet aggregation commonly used in the placement of STENTS in CORONARY ARTERIES.
ticlopidine : A thienopyridine that is 4,5,6,7-tetrahydrothieno[3,2-c]pyridine in which the hydrogen attached to the nitrogen is replaced by an o-chlorobenzyl group.
Heart Diseases: Pathological conditions involving the HEART including its structural and functional abnormalities.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Ticagrelor compared with clopidogrel reduces the incidence of stent thrombosis in patients with acute coronary syndromes, with consistent benefit across a broad range of patient, stent, and treatment characteristics." | 9.17 | Stent thrombosis with ticagrelor versus clopidogrel in patients with acute coronary syndromes: an analysis from the prospective, randomized PLATO trial. ( Emanuelsson, H; Harrington, RA; James, SK; Katus, HA; Lewis, BS; Mahaffey, KW; Maurer, G; Meier, B; Steg, PG; Storey, RF; Wallentin, L; Wojdyla, DM, 2013) |
| "The purpose of this study was to evaluate the effects of aspirin and clopidogrel response on myonecrosis after percutaneous coronary intervention (PCI) with glycoprotein (GP) IIb/IIIa blockade." | 9.13 | The effects of aspirin and clopidogrel response on myonecrosis after percutaneous coronary intervention: a BRIEF-PCI (Brief Infusion of Intravenous Eptifibatide Following Successful Percutaneous Coronary Intervention) trial substudy. ( Buller, C; Densem, C; Fox, R; Fung, A; Jokhi, P; Mancini, GB; Ricci, D; Saw, J; Starovoytov, A; Walsh, S; Wong, G, 2008) |
| "In patients presenting with ACS and receiving clopidogrel treatment after angiography (before or within 30 min of PCI), peri-procedural bivalirudin monotherapy suppresses acute and long-term adverse events to a similar extent as does UFH plus GP IIb/IIIa inhibitors, while significantly lowering the risk of bleeding complications." | 7.76 | Efficacy and safety of bivalirudin in patients receiving clopidogrel therapy after diagnostic angiography for percutaneous coronary intervention in acute coronary syndromes. ( Bergman, G; Feldman, DN; Minutello, RM; Moussa, I; Wong, SC, 2010) |
| "Ticagrelor compared with clopidogrel reduces the incidence of stent thrombosis in patients with acute coronary syndromes, with consistent benefit across a broad range of patient, stent, and treatment characteristics." | 5.17 | Stent thrombosis with ticagrelor versus clopidogrel in patients with acute coronary syndromes: an analysis from the prospective, randomized PLATO trial. ( Emanuelsson, H; Harrington, RA; James, SK; Katus, HA; Lewis, BS; Mahaffey, KW; Maurer, G; Meier, B; Steg, PG; Storey, RF; Wallentin, L; Wojdyla, DM, 2013) |
| "In patients undergoing nonurgent percutaneous coronary intervention and in comparison with clopidogrel, intravenous and oral elinogrel therapy did not significantly increase thrombolysis in myocardial infarction major or minor bleeding, although bleeding requiring medical attention was more common." | 5.16 | A randomized, double-blind, active-controlled phase 2 trial to evaluate a novel selective and reversible intravenous and oral P2Y12 inhibitor elinogrel versus clopidogrel in patients undergoing nonurgent percutaneous coronary intervention: the INNOVATE-PC ( Angiolillo, DJ; Berdan, LG; Bhatt, DL; French, WJ; Gibson, CM; Gretler, DD; Gurbel, PA; Harrington, RA; Huber, K; Kochman, J; Leonardi, S; Madan, M; McClure, MW; Paynter, G; Rao, SV; Thompson, VP; Welsh, RC; Zeymer, U, 2012) |
| "The purpose of this study was to evaluate the effects of aspirin and clopidogrel response on myonecrosis after percutaneous coronary intervention (PCI) with glycoprotein (GP) IIb/IIIa blockade." | 5.13 | The effects of aspirin and clopidogrel response on myonecrosis after percutaneous coronary intervention: a BRIEF-PCI (Brief Infusion of Intravenous Eptifibatide Following Successful Percutaneous Coronary Intervention) trial substudy. ( Buller, C; Densem, C; Fox, R; Fung, A; Jokhi, P; Mancini, GB; Ricci, D; Saw, J; Starovoytov, A; Walsh, S; Wong, G, 2008) |
| " Due to previous atrial fibrillation and ischaemic heart disease, this patient was treated with both dabigatran and clopidogrel." | 3.88 | Left ventricular mural thrombus despite treatment with dabigatran and clopidogrel. ( Fredgart, M; Gill, S, 2018) |
| "In patients presenting with ACS and receiving clopidogrel treatment after angiography (before or within 30 min of PCI), peri-procedural bivalirudin monotherapy suppresses acute and long-term adverse events to a similar extent as does UFH plus GP IIb/IIIa inhibitors, while significantly lowering the risk of bleeding complications." | 3.76 | Efficacy and safety of bivalirudin in patients receiving clopidogrel therapy after diagnostic angiography for percutaneous coronary intervention in acute coronary syndromes. ( Bergman, G; Feldman, DN; Minutello, RM; Moussa, I; Wong, SC, 2010) |
| " 2 patients who were treated with concomitant warfarin had bleeding complications (severe epistaxis and gastrointestinal bleeding)." | 3.74 | Safety and efficacy of clopidogrel in children with heart disease. ( Boshoff, D; Eyskens, B; Gewillig, M; Mertens, L, 2008) |
| "We sought to assess the effect of clopidogrel on in-hospital events in unselected patients with acute ST elevation myocardial infarction (STEMI)." | 3.74 | Clopidogrel in addition to aspirin reduces in-hospital major cardiac and cerebrovascular events in unselected patients with acute ST segment elevation myocardial. ( Bauer, T; Gitt, A; Gottwik, M; Heer, T; Jünger, C; Koeth, O; Mark, B; Senges, J; Zahn, R; Zeymer, U, 2008) |
| "Myocardial infarction was assessed using the third universal definition." | 2.82 | Effectiveness of platelet inhibition on major adverse cardiac events in non-cardiac surgery after percutaneous coronary intervention: a prospective cohort study. ( Beattie, WS; Carroll, J; Grewal, D; Harsha, P; Karkouti, K; Ragoonanan, T; Starzyk, Ł; Syed, S; Travis, G; Wąsowicz, M; Wijeysundera, DN, 2016) |
| "In one patient a transient ischemic attack occurred." | 2.78 | High versus standard clopidogrel loading in patients undergoing carotid artery stenting prior to cardiac surgery to assess the number of microemboli detected with transcranial Doppler: results of the randomized IMPACT trial. ( Ackerstaff, RG; Breet, NJ; De Vries, JP; Deneer, VH; Elsenberg, EH; Hackeng, CM; Kelder, JC; Schonewille, WJ; Suttorp, MJ; Ten Berg, JM; Tromp, SC; Van Der Heyden, J; Van Neerven, D; Van Werkum, J; Vos, JA; Wolters, F, 2013) |
| "This substudy of the Intravenous and Oral Administration of Elinogrel to Evaluate Tolerability and Efficacy in Nonurgent Percutaneous Coronary Intervention patients (INNOVATE-PCI) trial evaluated the pharmacokinetic and pharmacodynamic effects of two dosing regimens of IV followed by oral elinogrel (120 mg IV plus 100 mg oral twice daily; 120 mg IV plus 150 mg oral twice daily) versus standard clopidogrel therapy (300-600 mg oral loading dose plus 75 mg oral maintenance dose) in 56 patients undergoing nonurgent PCI." | 2.77 | Pharmacokinetic and pharmacodynamic effects of elinogrel: results of the platelet function substudy from the intravenous and oral administration of elinogrel to evaluate tolerability and efficacy in nonurgent percutaneous coronary intervention patients (I ( Angiolillo, DJ; Broderick, S; Buerke, M; Conley, PB; Dabrowski, M; Gurbel, PA; Harrington, RA; Jennings, LK; Kochman, J; McClure, MW; Neumann, FJ; Rao, SV; Saucedo, JF; Stephens, G; Stumpf, J; Trenk, D; Welsh, RC; Wójcik, J, 2012) |
| "Removal of the thrombus and maze procedure were performed at the same time." | 2.40 | [A case of mobile left atrial thrombus without mitral valve disease]. ( Asada, K; Hasegawa, Y; Kodama, T; Kondou, K; Matsuyama, N; Minohara, S; Okamoto, J; Okamoto, K; Sasaki, S; Sawada, Y, 1997) |
| "Although saddle embolism is a relatively rare event, orthopaedic surgeons should be aware of this condition." | 1.33 | Saddle embolism after corrective femoral osteotomy: a case report. ( Hoshino, Y; Kariya, Y; Konishi, H; Noguchi, K; Ohashi, Y; Sekiya, H, 2006) |
| "Among 801 patients not receiving treatment for thromboembolism, the annual rate was 0." | 1.30 | [Atrial fibrillation and thromboembolism: a multicenter cooperative study. Research Group for Antiarrhythmic Drug Therapy]. ( , 1998) |
| "With regard to thrombus dimensions, 1 patient treated with ticlopidine showed a decrease in thrombus size associated with a reduction of the scintigraphic activity." | 1.28 | Left ventricular thrombi: changes in size and in platelet deposition during treatment with indobufen and ticlopidine. ( Bellotti, P; Chiarella, F; Claudiani, F; Domenicucci, S; Lupi, G; Mazzotta, G; Scopinaro, G; Strada, P; Vecchio, C, 1990) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (6.67) | 18.2507 |
| 2000's | 27 (45.00) | 29.6817 |
| 2010's | 29 (48.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fredgart, M | 1 |
| Gill, S | 1 |
| Chen, Z | 1 |
| Qian, J | 1 |
| Chen, Y | 1 |
| Ma, J | 1 |
| Ge, J | 1 |
| Correll, M | 1 |
| Johnson, CK | 1 |
| Ferrari, G | 1 |
| Brizzio, M | 1 |
| Mak, AW | 1 |
| Quackenbush, J | 1 |
| Shaw, RE | 1 |
| Zapolanski, A | 1 |
| Grau, JB | 1 |
| D'Silva, A | 1 |
| Jassim, I | 1 |
| Greenwood, J | 1 |
| Grosser, K | 1 |
| Jacob, AK | 1 |
| Hurley, SP | 1 |
| Loughran, SM | 1 |
| Wetsch, TM | 1 |
| Trousdale, RT | 1 |
| Steg, PG | 1 |
| Harrington, RA | 4 |
| Emanuelsson, H | 1 |
| Katus, HA | 1 |
| Mahaffey, KW | 1 |
| Meier, B | 1 |
| Storey, RF | 1 |
| Wojdyla, DM | 1 |
| Lewis, BS | 1 |
| Maurer, G | 1 |
| Wallentin, L | 1 |
| James, SK | 1 |
| Cattaneo, M | 1 |
| Ottani, F | 1 |
| Mendiz, OA | 1 |
| Fava, CM | 1 |
| Lev, GA | 1 |
| Valdivieso, LR | 1 |
| Caponi, G | 1 |
| Hidalgo Alava, GF | 1 |
| Favaloro, RR | 1 |
| Robledo-Nolasco, R | 1 |
| Godínez-Montes de Oca, A | 1 |
| Zaballa-Contreras, JF | 1 |
| Suárez-Cuenca, JA | 1 |
| Mondragón-Terán, P | 1 |
| Rubio-Guerra, AF | 1 |
| Meléndez-Alcántara, MA | 1 |
| Lin, L | 2 |
| Wang, H | 1 |
| Chen, YF | 1 |
| Lin, WW | 1 |
| Wang, CL | 1 |
| Lin, CH | 1 |
| Ketterer, U | 1 |
| D'Ancona, G | 1 |
| Siegel, I | 1 |
| Ortak, J | 1 |
| Ince, H | 1 |
| Kische, S | 1 |
| Wąsowicz, M | 1 |
| Syed, S | 1 |
| Wijeysundera, DN | 1 |
| Starzyk, Ł | 1 |
| Grewal, D | 1 |
| Ragoonanan, T | 1 |
| Harsha, P | 1 |
| Travis, G | 1 |
| Carroll, J | 1 |
| Karkouti, K | 1 |
| Beattie, WS | 1 |
| Ozdemir, K | 1 |
| Aygül, N | 1 |
| Can, I | 1 |
| Aribaş, A | 1 |
| Mertens, L | 1 |
| Eyskens, B | 1 |
| Boshoff, D | 1 |
| Gewillig, M | 1 |
| Schäfer, A | 1 |
| Bauersachs, J | 1 |
| Eigenthaler, M | 2 |
| Selim, M | 1 |
| Saw, J | 1 |
| Densem, C | 1 |
| Walsh, S | 1 |
| Jokhi, P | 1 |
| Starovoytov, A | 1 |
| Fox, R | 1 |
| Wong, G | 1 |
| Buller, C | 1 |
| Ricci, D | 1 |
| Mancini, GB | 1 |
| Fung, A | 1 |
| García-Rinaldi, R | 1 |
| Carro-Pagán, C | 1 |
| Schaff, HV | 1 |
| McKellar, SH | 1 |
| Thompson, JL | 1 |
| Quiñones, J | 1 |
| Rodríguez-Acosta, JF | 1 |
| Erdem, G | 1 |
| Geisler, T | 1 |
| Flather, MD | 1 |
| Feldman, DN | 1 |
| Minutello, RM | 1 |
| Bergman, G | 1 |
| Moussa, I | 1 |
| Wong, SC | 1 |
| Gilchrist, IC | 1 |
| Patti, G | 1 |
| Chello, M | 1 |
| Pasceri, V | 1 |
| Colonna, D | 1 |
| Colonna, G | 1 |
| Pepe, LL | 1 |
| Montinaro, A | 1 |
| Covino, E | 1 |
| Di Sciascio, G | 1 |
| Tapp, LD | 1 |
| Lip, GYH | 1 |
| Lane, DA | 1 |
| Zhao, HJ | 1 |
| Zheng, ZT | 1 |
| Wang, ZH | 1 |
| Li, SH | 1 |
| Zhang, Y | 1 |
| Zhong, M | 1 |
| Zhang, W | 1 |
| El Ghannudi, S | 1 |
| Ohlmann, P | 1 |
| Jesel, L | 1 |
| Radulescu, B | 1 |
| El Adraa, E | 1 |
| Crimizade, U | 1 |
| Wiesel, ML | 1 |
| Gachet, C | 1 |
| Morel, O | 1 |
| Nam, D | 1 |
| Lerakis, S | 1 |
| Cardona, L | 1 |
| Ana, G | 1 |
| Luísa, B | 1 |
| Leal, A | 1 |
| António, F | 1 |
| Lídia, S | 1 |
| Cruz, FR | 1 |
| Jennings, LK | 2 |
| Michelson, AD | 1 |
| Jacoski, MV | 1 |
| Tyagi, A | 1 |
| Grgurevich, S | 1 |
| Li, JS | 1 |
| Angiolillo, DJ | 2 |
| Welsh, RC | 2 |
| Trenk, D | 1 |
| Neumann, FJ | 1 |
| Conley, PB | 1 |
| McClure, MW | 2 |
| Stephens, G | 1 |
| Kochman, J | 2 |
| Gurbel, PA | 2 |
| Wójcik, J | 1 |
| Dabrowski, M | 1 |
| Saucedo, JF | 1 |
| Stumpf, J | 1 |
| Buerke, M | 1 |
| Broderick, S | 1 |
| Rao, SV | 2 |
| Zeymer, U | 2 |
| Thompson, VP | 1 |
| Huber, K | 1 |
| Gretler, DD | 1 |
| Bhatt, DL | 1 |
| Gibson, CM | 1 |
| Berdan, LG | 1 |
| Paynter, G | 1 |
| Leonardi, S | 1 |
| Madan, M | 1 |
| French, WJ | 1 |
| Silvain, J | 1 |
| Montalescot, G | 1 |
| Renda, G | 1 |
| de Caterina, R | 1 |
| Zou, JJ | 1 |
| Xie, HG | 1 |
| Chen, SL | 1 |
| Tan, J | 1 |
| Zhao, YY | 1 |
| Xu, HM | 1 |
| Lin, S | 1 |
| Zhang, J | 1 |
| Wang, GJ | 1 |
| Van Der Heyden, J | 1 |
| Van Werkum, J | 1 |
| Hackeng, CM | 1 |
| Kelder, JC | 1 |
| Breet, NJ | 1 |
| Deneer, VH | 1 |
| Ackerstaff, RG | 1 |
| Tromp, SC | 1 |
| De Vries, JP | 1 |
| Vos, JA | 1 |
| Suttorp, MJ | 1 |
| Elsenberg, EH | 1 |
| Van Neerven, D | 1 |
| Schonewille, WJ | 1 |
| Wolters, F | 1 |
| Ten Berg, JM | 1 |
| Waksman, R | 1 |
| Ajani, AE | 1 |
| Pinnow, E | 1 |
| Cheneau, E | 1 |
| Leborgne, L | 1 |
| Dieble, R | 1 |
| Bui, AB | 1 |
| Satler, LF | 1 |
| Pichard, AD | 1 |
| Kent, KK | 1 |
| Lindsay, J | 1 |
| Collart, F | 1 |
| Derouck, D | 1 |
| Kerbaul, F | 1 |
| Feier, H | 1 |
| Mesana, TG | 1 |
| Hodgson, PK | 1 |
| Larsen, RL | 1 |
| SoRelle, R | 1 |
| Ahnadi, CE | 1 |
| Boughrassa, FF | 1 |
| Chapman-Montgomery, ES | 1 |
| Poisson, V | 1 |
| Gervais, A | 1 |
| Okrongly, D | 1 |
| Grant, AM | 1 |
| Grossmann, R | 1 |
| Sokolova, O | 1 |
| Schnurr, A | 1 |
| Bonz, A | 1 |
| Porsche, C | 1 |
| Obergfell, A | 1 |
| Lengenfelder, B | 1 |
| Walter, U | 1 |
| Vinholt, P | 1 |
| Poulsen, TS | 1 |
| Korsholm, L | 1 |
| Kristensen, SR | 1 |
| Hallas, J | 1 |
| Damkier, P | 1 |
| Mickley, H | 1 |
| Klinkhardt, U | 1 |
| Harder, S | 1 |
| Bramkamp, M | 1 |
| Dedes, KJ | 1 |
| Szucs, TD | 1 |
| Sekiya, H | 1 |
| Noguchi, K | 1 |
| Ohashi, Y | 1 |
| Kariya, Y | 1 |
| Hoshino, Y | 1 |
| Konishi, H | 1 |
| Toyoda, K | 1 |
| Okada, Y | 1 |
| Ibayashi, S | 1 |
| Inoue, T | 1 |
| Yasumori, K | 1 |
| Fukui, D | 1 |
| Uwatoko, T | 1 |
| Makihara, N | 1 |
| Minematsu, K | 1 |
| Cuisset, T | 1 |
| Frere, C | 1 |
| Quilici, J | 1 |
| Morange, PE | 1 |
| Saut, N | 1 |
| Lambert, M | 1 |
| Camoin, L | 1 |
| Vague, IJ | 1 |
| Bonnet, JL | 1 |
| Alessi, MC | 1 |
| Omeish, AF | 1 |
| Spiess, BD | 1 |
| van der Linden, J | 1 |
| Recio-Mayoral, A | 1 |
| Kaski, JC | 1 |
| McMurray, JJ | 1 |
| Horowitz, J | 1 |
| van Veldhuisen, DJ | 1 |
| Remme, WJ | 1 |
| Gitt, A | 1 |
| Jünger, C | 1 |
| Bauer, T | 1 |
| Heer, T | 1 |
| Koeth, O | 1 |
| Mark, B | 1 |
| Zahn, R | 1 |
| Senges, J | 1 |
| Gottwik, M | 1 |
| Matsuyama, N | 1 |
| Asada, K | 1 |
| Kondou, K | 1 |
| Kodama, T | 1 |
| Minohara, S | 1 |
| Hasegawa, Y | 1 |
| Sawada, Y | 1 |
| Okamoto, J | 1 |
| Okamoto, K | 1 |
| Sasaki, S | 1 |
| Galindo, G | 1 |
| Peiró, R | 1 |
| Plana, A | 1 |
| Navarro, MA | 1 |
| Berdié, J | 1 |
| Morató, J | 1 |
| Shukla, V | 1 |
| Bellotti, P | 1 |
| Claudiani, F | 1 |
| Chiarella, F | 1 |
| Domenicucci, S | 1 |
| Scopinaro, G | 1 |
| Mazzotta, G | 1 |
| Lupi, G | 1 |
| Strada, P | 1 |
| Vecchio, C | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| P2Y12 Inhibitors Utilization in Bifurcation and Chronic Total Occlusion PCI With Biologically Active Stents (P2BiTO) Registry[NCT01967615] | 4,500 participants (Actual) | Observational | 2015-01-31 | Completed | |||
| A Randomised, Double-blind, Parallel Group, Phase 3, Efficacy and Safety Study of Ticagrelor Compared With Clopidogrel for Prevention of Vascular Events in Patients With Non-ST or ST Elevation Acute Coronary Syndromes (ACS) [PLATO- a Study of PLATelet Inh[NCT00391872] | Phase 3 | 18,624 participants (Actual) | Interventional | 2006-10-31 | Completed | ||
| The Use of BRILInta to Optimize ANTiplatelet Therapy (BRILIANT) Registry: The BRILIANT KOREA Registry[NCT02521038] | 2,000 participants (Anticipated) | Observational [Patient Registry] | 2015-07-31 | Recruiting | |||
| Prospective Evaluation for Hybrid Cardiac Procedures[NCT05143671] | 111 participants (Anticipated) | Observational | 2021-05-13 | Recruiting | |||
| The Association Between Platelet Inhibition and Perioperative Major Adverse Cardiac Events In Post-Percutaneous Coronary Intervention (PCI) Patients Undergoing Non-Cardiac Surgery[NCT01707459] | 201 participants (Actual) | Observational | 2010-03-31 | Completed | |||
| Brief Infusion of Eptifibatide Following Percutaneous Coronary Intervention[NCT00111566] | Phase 4 | 624 participants (Actual) | Interventional | 2004-12-31 | Completed | ||
| A Randomized, Double-Blind, Active-Controlled Trial to Evaluate Intravenous and Oral PRT060128, a Selective and Reversible P2Y12 Inhibitor, vs Clopidogrel, as a Novel Antiplatelet Therapy in Patients Undergoing Non-Urgent PCI[NCT00751231] | Phase 2 | 652 participants (Actual) | Interventional | 2008-12-31 | Completed | ||
| Does the Magnitude of Platelet Inhibition Inversely Correlate With the Number of TCD-detected Microemboli in Asymptomatic Patients Undergoing Carotid Artery Stenting Prior to Cardiac Surgery Who Are Being Pre-treated With 300 mg or 600 mg Loading Dose of [NCT01146301] | Phase 4 | 0 participants | Interventional | 2008-03-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Participants with death from any cause, MI, or stroke. If no event, censoring occurs at the earliest of patient withdrawal of consent or date of scheduled withdrawal from therapy. ITT analysis of whole population. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: Randomization up to 12 months
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 901 |
| CLOPIDOGREL | 1065 |
Participants with death from vascular causes, MI, stroke, recurrent ischemia, or other thrombotic events. If no event, censoring occurs at the earliest of patient withdrawal consent or date of scheduled withdrawal from therapy. ITT analysis of whole population. Events were adjudicated. (NCT00391872)
Timeframe: Randomization up to 12 months
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 1290 |
| CLOPIDOGREL | 1456 |
Participants with death from vascular causes, MI, or stroke. If no event, censoring occurs at the earliest of patient withdrawal consent or date of scheduled withdrawal from therapy. ITT analysis of intent for invasive management population. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: Randomization up to 12 months
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 569 |
| CLOPIDOGREL | 668 |
Participants with death from vascular causes, MI, or stroke. If no event, censoring occurs at the earliest of patient withdrawal consent or date of scheduled withdrawal from therapy. Intention To Treat (ITT) analysis of whole population. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: Randomization up to 12 months
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 864 |
| CLOPIDOGREL | 1014 |
Participants with major (fatal/life-threatening or other) bleed by a study protocol scale based on need for treatment, number of transfusions, hemoglobin decrease, and other factors. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: First dosing up to 12 months
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 961 |
| CLOPIDOGREL | 929 |
Participants with a major CABG-related bleed by a study protocol scale based on need for treatment, number of transfusions, hemoglobin decrease, and other factors. All CABG surgeries were submitted for adjudication by an endpoint committee as potential bleeds. (NCT00391872)
Timeframe: First dosing up to 12 months
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 619 |
| CLOPIDOGREL | 654 |
Number of participants with a major fatal/life-threatening CABG-related bleed by a study protocol scale based on need for treatment, number of transfusions, hemoglobin decrease, and other factors. All CABG surgeries were submitted for adjudication by an endpoint committee as potential bleeds. (NCT00391872)
Timeframe: First dosing up to 12 months
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 329 |
| CLOPIDOGREL | 341 |
Participants with death from any cause. If no event, censoring occurs at the earliest of patient withdrawal consent or date of scheduled withdrawal from therapy. ITT (intention to treat) analysis of whole population. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: Randomization up to 12 months
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 399 |
| CLOPIDOGREL | 506 |
Participants with death from vascular causes. If no event, censoring occurs at the earliest of patient withdrawal consent or date of scheduled withdrawal from therapy. ITT (intention to treat) analysis of whole population. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: Randomization up to 12 months
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 353 |
| CLOPIDOGREL | 442 |
Participants with major (fatal/life-threatening or other) or minor bleed by a study protocol scale based on need for treatment, number of transfusions, hemoglobin decrease, and other factors. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: First dosing up to 12 months
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 1339 |
| CLOPIDOGREL | 1215 |
Participants with MI event. If no event, censoring occurs at the earliest of patient withdrawal consent or date of scheduled withdrawal from therapy. ITT (intention to treat) analysis of whole population. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: Randomization up to 12 months
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 504 |
| CLOPIDOGREL | 593 |
Participants with non CABG related major (fatal/life-threatening or other) bleed by a study protocol scale based on need for treatment, number of transfusions, hemoglobin decrease, and other factors. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: First dosing up to 12 months
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 362 |
| CLOPIDOGREL | 306 |
Participants with non-procedural major bleed by a study protocol scale based on need for treatment, number of transfusions, hemoglobin decrease, and other factors. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: First dosing up to 12 months
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 235 |
| CLOPIDOGREL | 180 |
Participants with stroke. If no event, censoring occurs at the earliest of patient withdrawal consent or date of scheduled withdrawal from therapy. ITT (intention to treat) analysis of whole population. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: Randomization up to 12 months
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 125 |
| CLOPIDOGREL | 106 |
Number of participants who were observed to have at least 1 ventricular pause of at least 3 seconds. Population is all patients who were observed over 2 week-long periods. Pauses were flagged algorithmically and confirmed by TIMI cardiologists. (NCT00391872)
Timeframe: 1-week period following randomization
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 21 |
| CLOPIDOGREL | 16 |
Number of participants who were observed to have at least 1 ventricular pause of at least 3 seconds. Population is all patients who were observed over 2 week-long periods. Pauses were flagged algorithmically and confirmed by Thrombolysis in Myocardial Infarction (TIMI) group cardiologists. (NCT00391872)
Timeframe: 1-week period following randomization
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 84 |
| CLOPIDOGREL | 51 |
10 reviews available for ticlopidine and Heart Diseases
| Article | Year |
|---|---|
Addition of cilostazol to conventional dual antiplatelet therapy reduces the risk of cardiac events and restenosis after drug-eluting stent implantation: a meta-analysis.
Topics: Aspirin; Cilostazol; Clopidogrel; Drug Therapy, Combination; Drug-Eluting Stents; Female; Heart Dise | 2013 |
High maintenance dose of clopidogrel in patients with high on-treatment platelet reactivity after a percutaneous coronary intervention: a meta-analysis.
Topics: Cerebrovascular Disorders; Chi-Square Distribution; Clopidogrel; Drug Resistance; Heart Diseases; He | 2015 |
[Clopidogrel--clinical use and potential therapeutic problems].
Topics: Angioplasty, Balloon, Coronary; Blood Vessel Prosthesis; Clopidogrel; Dose-Response Relationship, Dr | 2008 |
What goes into a major acute coronary syndrome trial and what will future trials look like?
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clinical Trials as Topic; Clopidogrel; Cyclic N-Oxides; | 2010 |
"Triple therapy" rather than "triple threat": a meta-analysis of the two antithrombotic regimens after stent implantation in patients receiving long-term oral anticoagulant treatment.
Topics: Administration, Oral; Anticoagulants; Aspirin; Clopidogrel; Drug Therapy, Combination; Heart Disease | 2011 |
Impact of antiplatelet therapy in heart disease.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Atrial Fibrillatio | 2012 |
The cost of new therapies in cardiovascular care. Time for hope or despair for developing countries.
Topics: Cardiovascular Diseases; Clopidogrel; Developing Countries; Heart Diseases; Hydroxymethylglutaryl-Co | 2007 |
Con: continuation of aspirin/clopidogrel for cardiac surgery.
Topics: Aspirin; Cardiac Surgical Procedures; Clopidogrel; Drug Therapy, Combination; Heart Diseases; Humans | 2007 |
Pro: continuation of aspirin/clopidogrel for cardiac surgery.
Topics: Aspirin; Cardiac Surgical Procedures; Clopidogrel; Heart Diseases; Humans; Platelet Aggregation Inhi | 2007 |
[A case of mobile left atrial thrombus without mitral valve disease].
Topics: Aged; Atrial Fibrillation; Cardiac Surgical Procedures; Female; Fibrinolytic Agents; Heart Atria; He | 1997 |
13 trials available for ticlopidine and Heart Diseases
38 other studies available for ticlopidine and Heart Diseases
| Article | Year |
|---|---|
Left ventricular mural thrombus despite treatment with dabigatran and clopidogrel.
Topics: Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Clopidogrel; Dabigatran; Diag | 2018 |
Mutational analysis clopidogrel resistance and platelet function in patients scheduled for coronary artery bypass grafting.
Topics: Aged; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cass | 2013 |
Chasing the ACE of hearts.
Topics: Angiotensin-Converting Enzyme Inhibitors; Aspirin; Clopidogrel; Drug Therapy, Combination; Electroca | 2013 |
Continuing clopidogrel during elective total hip and knee arthroplasty: assessment of bleeding risk and adverse outcomes.
Topics: Aged; Aged, 80 and over; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Blood Tran | 2014 |
[The ARCTIC study].
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Drug-Eluting Stents; Heart Diseases; Humans; Myocardi | 2013 |
Hybrid strategy for unstable patients with severe carotid and cardiac disease requiring surgery.
Topics: Aged; Angioplasty, Balloon; Anticoagulants; Aspirin; Cardiac Surgical Procedures; Carotid Artery Dis | 2015 |
Percutaneous left atrial appendage occlusion: Device thrombosis in clopidogrel non-responders.
Topics: Aged; Aged, 80 and over; Atrial Appendage; Atrial Fibrillation; Clopidogrel; Female; Heart Diseases; | 2016 |
Antiaggregant and anticoagulant therapy of free-floating thrombus in left atrium.
Topics: Adult; Anticoagulants; Aspirin; Clopidogrel; Diagnosis, Differential; Dyspnea; Echocardiography, Tra | 2008 |
Safety and efficacy of clopidogrel in children with heart disease.
Topics: Adolescent; Aspirin; Child; Child, Preschool; Clopidogrel; Female; Heart Diseases; Hemorrhage; Human | 2008 |
Antiplatelets for stroke prevention: implications of the PRoFESS trial.
Topics: Aspirin; Cerebral Hemorrhage; Clopidogrel; Delayed-Action Preparations; Dipyridamole; Drug Therapy, | 2009 |
Initial experience with dual antiplatelet thromboprophylaxis using clopidogrel and aspirin in patients with mechanical aortic prostheses.
Topics: Aged; Aortic Valve; Aspirin; Blood Platelets; Clopidogrel; Drug Combinations; Female; Follow-Up Stud | 2009 |
Efficacy and safety of bivalirudin in patients receiving clopidogrel therapy after diagnostic angiography for percutaneous coronary intervention in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Antithrombins; Chi | 2010 |
It is standard practice, but is it really best practice or clinical biocreep?
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Antithrombins; Clopidogrel; Coronary Angiog | 2010 |
What you need to know about Clopidogrel. This drug helps to prevent the blood clots that can cause heart attacks and stroke.
Topics: Clopidogrel; Health Knowledge, Attitudes, Practice; Heart Diseases; Humans; Myocardial Infarction; P | 2009 |
Optimal antithrombotic therapy in patients receiving long-term oral anticoagulation requiring percutaneous coronary intervention: "triple therapy" or "triple threat".
Topics: Administration, Oral; Anticoagulants; Aspirin; Clopidogrel; Drug Therapy, Combination; Heart Disease | 2011 |
Protect your heart during dental work. Don't stop taking aspirin, Plavix, or any other antiplatelet before dental work without asking your cardiologist.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Clopidogrel; Dental Care for Chronically Ill; Hear | 2011 |
Impaired inhibition of P2Y(12) by clopidogrel is a major determinant of cardiac death in diabetes mellitus patients treated by percutaneous coronary intervention.
Topics: Aged; Angioplasty, Balloon, Coronary; Cell Adhesion Molecules; Chi-Square Distribution; Clopidogrel; | 2011 |
The use of contrast echo to clear the left atrial appendage.
Topics: Aspirin; Atrial Appendage; Clopidogrel; Contrast Media; Drug Therapy, Combination; Echocardiography; | 2011 |
Thrombus formation on a left atrial appendage closure device.
Topics: Aged; Anticoagulants; Aspirin; Atrial Appendage; Atrial Fibrillation; Clopidogrel; Equipment Design; | 2011 |
Rapid P2Y12 inhibition: still an unmet medical need.
Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Female; Heart Diseases; Humans; Male; Platelet Aggregat | 2012 |
Regression of intracardiac heparin-induced thrombosis after aortic root surgery.
Topics: Aged; Anticoagulants; Aortic Aneurysm, Thoracic; Aspirin; Blood Vessel Prosthesis; Clopidogrel; Drug | 2003 |
Cardiology patient page. Antiplatelet therapy.
Topics: Aspirin; Blood Coagulation; Blood Platelets; Clopidogrel; Heart Diseases; Humans; Platelet Aggregati | 2003 |
Clopidogrel resistance marks recurrent risks.
Topics: Aged; Bibliometrics; Cardiology; Clopidogrel; Cohort Studies; Coronary Restenosis; Drug Resistance; | 2004 |
Comparison of two methods to assess variability of platelet response to anti-platelet therapies in patients with acute coronary syndrome undergoing angioplasty.
Topics: Abciximab; Aged; Angioplasty; Antibodies, Monoclonal; Blood Platelets; Cell Count; Clopidogrel; Edet | 2004 |
Heart-protective drugs: a primer. Back to basics on how they work, side effects, interactions.
Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme | 2004 |
The antiplatelet effect of clopidogrel is not attenuated by statin treatment in stable patients with ischemic heart disease.
Topics: Aged; Atorvastatin; Blood Platelets; Cholesterol, LDL; Clopidogrel; Cytochrome P-450 CYP3A; Cytochro | 2005 |
Flow cytometric measurement of platelet-leukocyte aggregates: a possible target to monitor platelet function?
Topics: Adenosine Diphosphate; Adult; Arterial Occlusive Diseases; Aspirin; Blood Platelets; Clopidogrel; Fl | 2005 |
Pharmacotherapy of acute coronary syndromes: medical economics with an emphasis on clopidogrel.
Topics: Acute Disease; Clopidogrel; Cost-Benefit Analysis; Drug Costs; Economics, Medical; Fibrinolytic Agen | 2005 |
Saddle embolism after corrective femoral osteotomy: a case report.
Topics: Arterial Occlusive Diseases; Atrial Fibrillation; Echocardiography, Transesophageal; Embolectomy; Em | 2006 |
[When ASS, when anticoagulants?].
Topics: Administration, Oral; Age Factors; Aged; Anticoagulants; Aspirin; Clopidogrel; Female; Heart Disease | 2006 |
Antithrombotic therapy and predilection for cerebellar hemorrhage.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anticoagulants; Arteriosclerosis; Aspirin; Blo | 2007 |
Role of the T744C polymorphism of the P2Y12 gene on platelet response to a 600-mg loading dose of clopidogrel in 597 patients with non-ST-segment elevation acute coronary syndrome.
Topics: Acute Disease; Aged; Blood Platelets; Cell Adhesion Molecules; Clopidogrel; Drug Resistance; Electro | 2007 |
Clinical trials update from the European Society of Cardiology Congress in Vienna, 2007: PROSPECT, EVEREST, ARISE, ALOFT, FINESSE, Prague-8, CARESS in MI and ACUITY.
Topics: Abciximab; Acute Coronary Syndrome; Amides; Antibodies, Monoclonal; Benzazepines; Clinical Trials as | 2007 |
Clopidogrel in addition to aspirin reduces in-hospital major cardiac and cerebrovascular events in unselected patients with acute ST segment elevation myocardial.
Topics: Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Aspirin; Cerebrovascular Disorders; Clopido | 2008 |
[Atrial fibrillation and thromboembolism: a multicenter cooperative study. Research Group for Antiarrhythmic Drug Therapy].
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Dipyridamole; Female; Heart Diseases; Humans; Male; Mi | 1998 |
[Prevention of thromboembolic disease in patients with heart disease].
Topics: Age Factors; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Cross-Sectional Studies; Dipyridamole | 2000 |
Clopidogrel(TM): an alternative to acetylsalicylic acid and ticlopidine in antiplatelet therapy?
Topics: Arteriosclerosis; Canada; Cost-Benefit Analysis; Drug Evaluation; Heart Diseases; Humans; Ischemic A | 1999 |
Left ventricular thrombi: changes in size and in platelet deposition during treatment with indobufen and ticlopidine.
Topics: Echocardiography; Heart Diseases; Humans; Indium Radioisotopes; Isoindoles; Phenylbutyrates; Platele | 1990 |